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Objective: To evaluate the in vitro activities of the ethyl acetate (EA) fraction of
Houttuynia cordata (H. cordata) Thunb. (Saururaceae) and three of its constituent ﬂa-
vonoids (quercetin, quercitrin and rutin) against murine coronavirus and dengue virus
(DENV).
Methods: The antiviral activities of various concentrations of the EA fraction of
H. cordata and ﬂavonoids were assessed using virus neutralization tests against mouse
hepatitis virus (MHV) and DENV type 2 (DENV-2). Cinanserin hydrochloride was also
tested against MHV. The EA fraction of H. cordata was tested for acute oral toxicity in
C57BL/6 mice.
Results: The EA fraction of H. cordata inhibited viral infectivity up to 6 d. Cinanserin
hydrochloride was able to inhibit MHV for only 2 d. The 50% inhibitory concentrations
(IC50) of the EA fraction of H. cordata added before the viral adsorption stage were
0.98 mg/mL for MHV and 7.50 mg/mL for DENV-2 with absence of cytotoxicity. The
mice fed with the EA fraction up to 2000 mg/kg did not induce any signs of acute
toxicity, with normal histological features of major organs. Certain ﬂavonoids exhibited
comparatively weaker antiviral activity, notably quercetin which could inhibit both MHV
and DENV-2. This was followed by quercitrin which could inhibit DENV-2 but not
MHV, whereas rutin did not exert any inhibitory effect on either virus. When quercetin
was combined with quercitrin, enhancement of anti-DENV-2 activity and reduced
cytotoxicity were observed. However, the synergistic efﬁcacy of the ﬂavonoid combi-
nation was still less than that of the EA fraction.
Conclusions: The compounds in H. cordata contribute to the superior antiviral efﬁcacy
of the EA fraction which lacked cytotoxicity in vitro and acute toxicity in vivo. H. cordata
has much potential for the development of antiviral agents against coronavirus and
dengue infections.1. Introduction
Severe acute distress syndrome (SARS) is a highly conta-
gious respiratory illness caused by SARS coronavirus, whichemerged in 2003 and rapidly spread throughout the world, with a
mortality rate of 10%–15%. Although the disease disappeared in
mid-2003, its re-emergence cannot be excluded since SARS-like
coronaviruses are zoonotic and exist in animal reservoirs (e.g.,
bats, raccoon dogs and palm civets), thus posing a potential risk
for future epidemics [1–3]. SARS coronavirus is a large,
enveloped, single-strand, positive-sense RNA virus. The viral
genome is about 30 kbp, containing open reading frames that
encode the polymerases required for viral RNA synthesis, while
the remaining open reading frames encode structural proteinsarticle under the CC BY-NC-ND license (http://
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sory proteins.
First identiﬁed in 2012, the emerging Middle East respiratory
syndrome (MERS) coronavirus causes severe pneumonia
with multiorgan involvement (including acute renal failure), and
a mortality rate of 36% (446 deaths out of 1 244 cases docu-
mented by WHO as of 9 June 2015). It is considered to be
a zoonotic virus being transmitted from camels in the Middle
East. Currently, no speciﬁc treatment exists against MERS
coronavirus.
The murine coronavirus, mouse hepatitis virus (MHV), is a
coronavirus that causes an epidemic murine illness with high
mortality. Generally, MHV is extremely infectious to colonies of
mice and causes hepatitis upon infection. SARS, MERS and
MHV belong to the group 2 coronaviruses and are classiﬁed
under the genus Betacoronavirus. In view of the relatedness of
these coronaviruses, MHV was selected in this study to act as a
surrogate model for SARS and MERS coronaviruses which
necessitate BSL-3 facilities, whereas MHV is considered a BSL-
2 pathogen.
Belonging to the genus Flavivirus, dengue virus (DENV)
represents the most important mosquito-borne viral disease with
considerable resurgence in many parts of the world. There are
four antigenically-related but distinct DENV serotypes, such that
infection with one serotype does not confer life-long immunity
against the other serotypes. DENV infection causes dengue fe-
ver, and occasionally the more serious conditions of dengue
hemorrhagic fever and dengue shock syndrome [4]. Antibody-
dependent enhancement is thought to play a central role in
dengue pathogenesis, with the risk of developing dengue hem-
orrhagic fever and/or dengue shock syndrome being greater in
secondary infections with DENV-2 compared to other serotypes
[5]. The different manifestations of dengue may also be attributed
to DENV variants with varying degrees of virulence [6], while
viral load is also a contributing factor in the development of
potentially fatal complications [7]. In addition, being a highly
prevalent serotype in tropical and subtropical regions
worldwide, DENV-2 was selected for this study. Although
several dengue candidate vaccines are undergoing clinical trials,
there are currently no effective antiviral therapies which are
urgently needed to control dengue.
Belonging to the Saururaceae family, Houttuynia cordata
(H. cordata) Thunb. is a perennial plant native to mountainous
regions of eastern Asia, with an indeﬁnite spread as a creeping
rhizome in moist locations. This herb possesses very promising
antiviral properties especially against clinically important
enveloped viruses such as herpes simplex virus-1 (HSV-1),
inﬂuenza virus, and human immunodeﬁciency virus-1 in vitro.
Interestingly, the steam distillate of H. cordata can strikingly
inactivate an enveloped virus but is incapable of inactivating a
non-enveloped virus [8–12].
To support these observations, we and others have demon-
strated that the ethyl acetate (EA) fraction of H. cordata is
effective in inhibiting the infectivity of enveloped viruses such
as DENV [13]. Meng et al. discovered 11 common peaks in the
HPLC-DAD MS ﬁngerprint of fresh H. cordata [14]. In our
previous project, we veriﬁed some of these peaks in the EA
extract as polyphenols or ﬂavonoids (chlorogenic acid,
hyperoside, quercetin and quercetrin) and have investigated
their antiviral efﬁcacy against DENV [13]. Flavonoids are a
class of natural products with high pharmacological potency,
are ubiquitous in photosynthesizing cells and hence likely tobe consumed daily [15]. Flavonoids are known to display
antiviral activities, e.g., glabranine and 7-O-methyl-glabranine
against dengue virus, procyanidin and pelargonidin against
HSV, and catechins against inﬂuenza virus [16,17].
Using virus-speciﬁc neutralization tests, this study tested
the EA fraction of H. cordata for its antiviral efﬁcacy against
MHV (for the ﬁrst time) and DENV-2 (as further veriﬁcation
using a different batch of H. cordata specimen). Three ﬂavo-
noid components of H. cordata, i.e., quercetin, quercitrin
and rutin, were also investigated for their antiviral activities
against both viruses. They were also selected since they are
common and naturally occurring ﬂavonoids, whose molecular
structures share high degrees of similarity. In the MHV ex-
periments, we also compared the potency of cinanserin hy-
drochloride which has been proven to neutralize SARS
coronavirus in vitro. All the compounds were also tested for
cytotoxicity in vitro, while the EA fraction was also tested for
acute oral toxicity in mice.
2. Methods and materials
2.1. Plant material, ethanolic extraction, aqueous-EA
fractionation, and ﬂavonoids of H. cordata
The aerial parts (fresh leaves) of H. cordata were collected
from a farm in Johor, Malaysia and authenticated in the
Department of Pharmacology, National University of Singapore.
The voucher specimen of H. cordata was deposited in the
Singapore Botanic Gardens and assigned the identiﬁcation
number SING2011-203. Prior to extraction, the herb (dry weight
of 500 g) was washed with de-ionized water, homogenized to a
ﬁne powder, and soaked overnight in 80% (v/v) ethanol. The
next day, the ethanolic extract was removed and stored. More
solvent was added to the blended herb, which was left to soak till
exhaustion. The extract was ﬁltered, concentrated with a rotary
evaporator (Buchi Rotavapor R-144) and freeze-dried to yield
19.28 g of crude extract in powder form. The crude extract was
then dissolved in EA and de-ionized water. The water and EA
phases were separated with a separating funnel. The EA phase
was concentrated with a rotary evaporator, and the concentrated
EA fraction was subsequently stored at −80 C overnight and
freeze-dried. The ﬂavonoids tested were quercetin dihydrate
(98% HPLC), quercitrin, and rutin hydrate (95%), all pur-
chased from Sigma–Aldrich.
2.2. Mouse hepatitis virus, cell culture, and
neutralization test
CCL9.1, a normal Mus musculus (mouse) liver epithelial cell
line, was used for propagation of MHV and for the MHV
neutralization test. Compounds that were tested against MHV
were the EA fraction of H. cordata, its ﬂavonoid components,
and cinanserin hydrochloride (Tocris Bioscience). Each com-
pound was 2-fold serially diluted with the corresponding diluent,
and the dilutions were then added to wells of a 96-well micro-
titer plate. Next, 100 TCID50 of MHV was added to each diluted
compound and incubated at 37 C for 1 h with 5% CO2. Also
tested was treatment with diluent only at various concentrations.
Virus-infected controls and uninfected cell controls were
included in each batch of assays. Conﬂuent CCL9.1 cells were
cultured in DMEM supplemented with 10% horse serum, and
1 × 105 cells were seeded into each well of another 96-well
Table 1
IC50, CC50 and selectivity indices of H. cordata fraction, ﬂavonoids, and
cinanserin against MHV.
Sample IC50 (mg/mL) CC50 (mg/mL) Selectivity index
EA fraction 0.98 NCa >4.00b
Quercetin 125.00 116.52 0.93
Quercitrin NIL NCa NIL
Rutin NIL NCa NIL
Cinanserin (1 dpi) 31.25 NCa >4.00c
Cinanserin (2 dpi) 62.50 NCa >2.00c
a NC: No cytotoxicity at all concentrations tested against CCL9.1 cells.
b Highest selectivity index of EA fraction (i.e., lowest concentration for
viral inhibition coupled with absence of cytotoxicity). c Selectivity index
with absence of cytotoxicity.
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cells were 80% conﬂuent. Cell culture ﬂuid from each well was
discarded. Each virus-compound mixture and controls were
transferred to these wells in duplicate, followed by addition of
DMEM with 10% (v/v) horse serum. The plate was sealed and
incubated at 37 C with 5% CO2, and observed daily for 6 d.
The highest dilution of compound that inhibited cytopathic ef-
fects (CPE) was considered as the minimum inhibitory con-
centration (MIC).
2.3. Dengue virus, cell culture, and plaque reduction
neutralization test
The New Guinea C strain of DENV-2 was propagated in the
C6/36 Aedes albopictus mosquito cell line and maintained in
Leibovitz L15 medium supplemented with 3% (v/v) fetal
bovine serum at 28 C under 5% CO2 atmosphere. The anti-
DENV-2 activity of H. cordata and its ﬂavonoids were eval-
uated by plaque reduction neutralization test or PRNT [18,19].
BHK-21 (baby hamster kidney) ﬁbroblasts were cultured to
form cell monolayers in 24-well plates with RPMI-1640 sup-
plemented with 10% (v/v) fetal bovine serum at 37 C under
5% CO2. The test compounds were dissolved in the relevant
diluents, and 2-fold serial dilutions were prepared to obtain
different concentrations. DENV-2 New Guinea C neutralizing
monoclonal antibody 3H5 from Chemicon served as the pos-
itive control [20]. Diluent only (at various concentrations),
virus, and cell controls were also included by adding the
corresponding diluent, virus suspension, and medium without
the treatment compounds. Each experiment was performed in
duplicate. DENV-2 (90 plaque-forming units or PFU) were
incubated for 1 h with various concentrations of each com-
pound together with controls before adding to the cells. The
virus-sample mixtures were incubated with the cells at 37 C
under 5% CO2 for another hour with rocking at 15-min in-
tervals before the cells were overlaid with 1% carboxymeth-
ylcellulose at 37 C under 5% CO2 for 6 d. The cells were then
ﬁxed with 20% formaldehyde and stained with 1% crystal
violet, and the number of plaques was counted. The percentage
plaque reduction of the compounds at every dilution was
determined as follows: (mean number of plaques in virus
control) − (average number of plaques in sample) × 100%
divided by (mean number of plaques in virus control). The
percentage plaque reduction was plotted against various con-
centrations of the test agents to determine the concentration
that causes 50% plaque reduction (IC50).
2.4. MTT cell viability and proliferation assay
The MTT cell proliferation assay was performed to determine
the cell viability following exposure to the test compounds.
Various concentrations of each test compound were added to
wells containing cell monolayers and incubated at 37 C under
5% CO2 for 48 h. After incubation, MTT reagent was added to
each well, and further incubated for 4 h or until purple pre-
cipitates were visible under an inverted microscope. Then,
100 mL of 100 g/L SDS in 0.01 mol/L HCl were added to each
well and incubated overnight in the dark at room temperature.
The optical density (OD) at 570 nm was then read, and the cell
inhibition rate calculated from the formula: [1 − (OD of sample
with cells) − (OD of sample without cells) divided by (OD of
solvent with cells) − (OD of medium without cells)] × 100%.The inhibition rates were plotted against various sample con-
centrations to ascertain the concentration that causes 50%
cytotoxicity (CC50). The EA fraction and ﬂavonoids (either
individually or in combination) were tested at the same con-
centrations as those for neutralization tests. The assay included
wells containing medium only as well as untreated control cells.
Each experiment was repeated, and the mean and standard de-
viation were calculated.
2.5. Acute oral toxicity testing
This approach was adapted from the OECD Guideline for
Testing of Chemicals, 420: Acute Oral Toxicity – Fixed Dose
Procedure, and relied on the observation of clear signs of
toxicity or even mortality. C57/BL6 nulliparous and non-
pregnant female mice about 8-weeks old were obtained from
the Laboratory Animals Center, National University of
Singapore. Upon arrival, they were kept in cages for 5 d prior to
commencement of the study. On the actual dose-feeding day, the
mice were fasted for about 4 h. Doses of 100, 500, 1000 and
2000 mg/kg were prepared for administration using water as
vehicle to suspend the ethanolic extract of H. cordata at a
constant volume of 1 mL/100 g of body weight. In total, the ﬁve
groups of mice (n = 2 each) were fed with a single dose of the
extract (including the vehicle control) by oral gavage. A sighting
study was then conducted frequently from the ﬁrst 30 min, with
special attention to the ﬁrst 4 h. Thereafter, the condition of each
mouse was observed daily to detect abnormalities such as
changes in physical appearance, behavioral signs and body
weight. All mice were ﬁnally euthanized after 14 d of obser-
vation, and major organs (brain, heart, lungs, liver and kidneys)
were harvested for histopathological examination after staining
with hematoxylin and eosin (H&E).
3. Results
3.1. Anti-MHV activities of EA fraction of H. cordata,
quercetin and cinanserin
The EA fraction of H. cordata was evaluated at concentra-
tions of 3.91 mg/mL down to 0.24 mg/mL. Table 1 and Figure 1
show that the EA fraction of H. cordata exhibited anti-MHV
activity at a MIC of 0.98 mg/mL without any apparent cyto-
toxic effects on CCL9.1 cells.
Tested at concentrations from 500.00 to 15.63 mg/mL, the
anti-MHV effect of quercetin was signiﬁcantly less, with MIC
Figure 1. Neutralization of MHV infectivity by the EA fraction of H. cordata on 2 dpi.
(A) Uninfected control of CCL9.1 cells. (B) MHV-infected CCL9.1 cells control. (C) MHV-infected CCL9.1 cells subjected to 0.98 mg/mL of EA fraction.
(D) MHV-infected CCL9.1 cells subjected to 0.49 mg/mL of EA fraction. Absence of obvious CPE in (C) indicates neutralization of MHV infectivity.
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116.50 mg/mL, and selectivity index of 0.93. However, quer-
citrin and rutin did not exhibit antiviral activity on 2 days post-
infection (dpi) at concentrations of 500.00 mg/mL and below
(Table 1).
Cinanserin hydrochloride was tested at concentrations ranging
from 125.00 to 3.91 mg/mL. Table 1 indicates that cinanserin
exerted anti-MHV activity at MIC of 31.25 mg/mL on 1 dpi and
62.50 mg/mL on 2 dpi (Figure 3), with minimal or no cytotox-
icity. However, on 3 dpi, no viral inhibition was observed.
3.2. Anti-DENV-2 activities of EA fraction of H. cordata,
quercetin and/or quercetrin
The EA fraction of H. cordata was tested starting with the
highest concentration of 166.67 mg/mL followed by 2-fold di-
lutions down to 0.08 mg/mL. By means of PRNT, a distinct trend
of DENV-2 inhibition was observed at various concentrations of
the EA fraction without cytotoxicity to BHK cells, with the IC50
being 7.50 mg/mL. The efﬁcacy of the EA fraction in inhibiting
DENV-2 infection was clearly evident at concentrations of
20.83 mg/mL and above, at which complete viral inhibition was
achieved (Figure 4).
Individual ﬂavonoids were tested at concentrations of
500.00 mg/mL down to 15.63 mg/mL. Table 2 indicates that
quercetin displayed anti-DENV-2 activity with an IC50 of
176.76 mg/mL, CC50 value of 155.38 mg/mL, and selectivity
index of 0.88. Although quercitrin showed less activity against
DENV-2 with an IC50 of 467.27 mg/mL, this ﬂavonoid did not
cause cytotoxicity to BHK cells. Similar to experiments withFigure 2. Neutralization of MHV infectivity by quercetin (dissolved in aqueo
(A) Uninfected control of CCL9.1 cells. (B) MHV-infected CCL9.1 cells contro
MHV-infected CCL9.1 cells subjected to 62.5 mg/mL of quercetin. Absence o
Figure 3. Neutralization of MHV infectivity by cinanserin hydrochloride on 2
(A) Uninfected control of CCL9.1 cells. (B) MHV-infected CCL9.1 cells contro
(D) MHV-infected CCL9.1 cells treated with 62.5 mg/mL of cinanserin. (E) MH
obvious CPE in (D) and (E) indicates neutralization of MHV infectivity.MHV, no anti-DENV-2 activity was detected with rutin treat-
ment (without cytotoxicity).
Given that quercetin and quercitrin individually exhibited
anti-DENV-2 properties, we evaluated whether the combination
of both ﬂavonoid compounds (at 1:1 ratio) could exert enhanced
DENV-2 inhibition. Indeed, this combination of components
achieved a synergistic anti-DENV-2 effect and lower cytotox-
icity, with improved corresponding values of IC50 (158.21 mg/
mL), CC50 (270.00 mg/mL), and selectivity index (1.71), as
shown in Table 2.
3.3. Absence of non-speciﬁc virus inhibition and
cytotoxicity of DMSO and aqueous alkali solvents
The EA fraction, quercetrin and rutin were dissolved in 1%
DMSO. Quercetin was dissolved in aqueous alkali (0.06 mol/L
NaOH) as it was not very soluble in DMSO. Various concen-
trations of EA fraction and compounds were subjected to the
corresponding viral neutralization tests as well as the MTT
assay. As negative controls, DMSO and aqueous alkali were also
tested separately by DENV-2 PRNT, MHV neutralization test
and the MTT assay which revealed absence of non-speciﬁc
DENV-2 and MHV inhibition as well as lack of cytotoxicity
of these solvents (data not shown).
3.4. Absence of acute toxicity and pathology in mice
after oral feeding with H. cordata extract
Throughout the 14-day period of observation, the control
group as well as the four groups of mice fed with varying dosesus alkali) on 2 dpi.
l. (C) MHV-infected CCL9.1 cells subjected to 125 mg/mL of quercetin. (D)
f obvious CPE in (C) indicates neutralization of MHV infectivity.
dpi.
l. (C) MHV-infected CCL9.1 cells treated with 31.25 mg/mL of cinanserin.
V-infected CCL9.1 cells treated with 125 mg/mL of cinanserin. Absence of
Figure 4. The EA fraction of H. cordata inhibits DENV-2 infectivity but is
not cytotoxic to BHK-21 cells.
The EA fraction of H. cordata was tested at concentrations of 166.67 mg/
mL down to 0.08 mg/mL. The upper plot reveals a distinct trend of DENV-2
inhibition, with the IC50 being 7.5 mg/mL, and complete viral inhibition
being achieved at concentrations of 20.83 mg/mL and above. The lower plot
shows that no cytotoxicity to BHK-21 cells was evident at various con-
centrations of the EA fraction tested.
Table 2
IC50, CC50 and selectivity indices of H. cordata fraction, ﬂavonoids, and
their combination against DENV-2.
Sample IC50 (mg/
mL)
CC50 (mg/
mL)
Selectivity
index
EA fraction 7.50 NCa >22.22b
Quercetin 176.76 155.38 0.88
Quercitrin 467.27 NCa >1.07c
Quercetin + Quercitrin 158.21 270.00 1.71
Rutin NIL NCa NIL
a NC: No cytotoxicity at all concentrations tested against BHK-21 cells.
b Highest selectivity index of EA fraction (i.e., lowest concentration for
viral inhibition coupled with absence of cytotoxicity). c Selectivity index
with absence of cytotoxicity.
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weight loss (data not shown). Moreover, all mice appeared to be
active and well-groomed before euthanasia. From the histo-
pathological sections of all major organs stained with H&E,
there was no signiﬁcant difference between the control group
and all the test groups, as exempliﬁed in Figure 5 which depicts
the control group compared with the group fed with the highest
dose of 2000 mg/kg.Figure 5. The EA fraction of H. cordata does not cause acute oral toxicity in
Representative histopathological sections of major organs stained with H&E for
of EA fraction of H. cordata (images F–J). (A, F) Brain with (a) nuclei of neu
alveolar duct; (e) alveoli; (f) blood vessel. (C, H) Heart with (g) cardiac muscl
glomeruli.4. Discussion
The experimental strategy in this study was to investigate the
prophylactic antiviral effects since the compounds were allowed
to interact with the viruses for 1 h before introduction into the
cells. This approach was employed as we previously found no
therapeutic effect when the compounds were added after prior
infection of cells with DENV [13].
Overall, this study demonstrated that EA fraction of
H. cordata and its ﬂavonoid component, quercetin, could inhibit
both MHV and DENV-2 in vitro. This was followed by quer-
citrin which could inhibit DENV-2 but not MHV, whereas rutin
did not exert any inhibitory effect on both viruses. We and
others have provided evidence to show that different ﬂavonoid
components in the EA fraction of H. cordata exert varying de-
grees of antiviral activity against different viruses. Our ﬁndings
corroborate previous evidence that among the ﬂavonoid com-
ponents, quercetin is the most effective against DENV-2 [13].
Wleklik et al. emphasized that there is a structural basis for
the distinct differences in antiviral activities of ﬂavonoids [21].
Hence, it is noteworthy that being the most bioactive,
quercetin possesses the hydroxyl group at the R2 position
compared to the other two ﬂavonoids tested, i.e., rhamnose in
quercitrin and rubinose in rutin [22].
Quercetin is an aglycone present at high concentration in
onions. This compound has virucidal activity against enveloped
viruses such as mengovirus, herpes simplex, parainﬂuenza type
3, pseudorabies, respiratory syncytial, and Sindbis viruses [23–
26]. Quercetin is able to inhibit H+-ATPase of lysosomal
membrane and thus prevent virus coat removal [15]. Moreover,
quercetin exhibits signiﬁcant inhibitory effects on the ATPase
of multidrug resistance-associated proteins, thus increasing the
bioavailability of anticancer and antiviral drugs in vivo [27].
Hence, quercetin can be considered for its potential efﬁcacy in
antiviral drug therapies.
Quercitrin (quercetin-3-L-rhamnoside) and rutin (quercetin-3-
rutinoside) occur as glycosides. Quercitrin appears to show the
highest content in ﬁngerprint analysis of H. cordata by HPLC
[14]. Among the ﬂavonoids, quercetin also exerts the highest
activity on HSV-1, whilst rutin has no effect at all [21]. This
characteristic implies that the substitution or addition of free
hydroxyl group at certain positions may culminate in a
decreased or even completely abolished antiviral effect. Suchmice.
the vehicle control group (images A–E) and test group fed with 2000 mg/kg
rons; (b) blood capillary. (B, G) Lung with (c) respiratory bronchiole; (d)
e. (D, I) Liver with (h) central vein; (i) hepatocytes. (E, J) Kidney with (j)
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development of more active and less toxic ﬂavonoids with
appropriate pharmacokinetic properties. Hence, they may pave
the way for novel compounds that can match or even exceed the
efﬁcacies of existing antiviral drugs [26,28,29].
Another interesting aspect was the enhancement of anti-
DENV-2 activity of quercetin when combined with quercitrin.
Besides augmenting the antiviral effect, this combination also
reduced the cytotoxicity relative to that induced by quercetin
alone. This characteristic reiterates that combinations of com-
ponents with greater anti-dengue efﬁcacy but lower toxicity are
potentially promising, as discovered previously using combi-
nations of quercetin, chlorogenic acid and/or hyperoside [13].
Indeed, several reports have already documented the
synergistic antiviral effects of combinations of individual
ﬂavonoids against viral pathogens, such as herpesviruses and
fowlpox virus [30,31].
Although cinanserin was able to inhibit MHV at 31.25 mg/
mL on 1 dpi and 62.5 mg/mL on 2 dpi, its effect was relatively
short-lived and it could not inhibit MHV from 3 dpi onwards. In
comparison, however, we observed that the EA fraction and
quercetin yielded a longer-lasting antiviral effect of up to 6 d.
This ﬁnding may be explained by superimposition of the two
3C-like proteinases of MHV and SARS CoV which illustrates
that certain amino acid residues residing within 7 Å of the active
site (C145) are different (not shown). Thus, these amino acid
disparities may inﬂuence recognition and binding of cinanserin
hydrochloride to the active site and may also lead to its lower
afﬁnity for 3C-like proteinase of MHV than SARS-coronavirus.
Competitive binding of cinanserin hydrochloride to the active
site of 3C-like proteinase hinders the processing of the precursor
polyprotein to generate functional replicase necessary for viral
replication [32–34].
Importantly, the EA fraction of H. cordata was capable of
inhibiting both DENV-2 and MHV in vitro at relatively low
concentrations with negligible cytotoxicity and very good
selectivity indices. Moreover, the EA fraction was also more
potent than all the individual compounds tested (including their
combination) and did not cause any cytotoxicity to mammalian
kidney (BHK) and liver (CCL9.1) cell lines in vitro, nor any
acute toxicity or pathology of major murine organs in vivo. This
feature reiterates the synergistic effects of the combination of
multiple ﬂavonoids and other constituents within H. cordata that
confer optimal antiviral activities and minimal toxicity [35], in
keeping with the majority of successful traditional Chinese
medicine.
Our study lends support to the accumulating literature that
the EA fraction of H. cordata indeed represents a highly
promising prophylactic agent against coronaviruses and dengue
viruses [36–38]. To complement this study, future in vivo studies
are warranted to assess the efﬁcacy of the EA fraction of
H. cordata against coronaviruses and dengue viruses using the
relevant mouse models [39]. However, further in vivo
experiments are necessary to further assess the long-term
safety of H. cordata as an antiviral agent in biological sys-
tems, including acquiring crucial information on its adsorption,
distribution, metabolism and elimination. To address the
important issue of batch-to-batch variation, greater efforts
should also focus on the quality control of extracts derived from
this medicinal plant. Finally, the mechanisms of action of the EA
fraction and its constituent ﬂavonoids against viruses at the
molecular level need to be further elucidated [40].Conﬂict of interest statement
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